Skip to main content

Advertisement

SpringerLink
Log in

Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Dovitinib is a small molecule kinase inhibitor with activity against the fibroblast growth factor and vascular endothelial growth factor receptor families. The purpose of this phase Ib study was to define the recommended phase 2 dose of the combinations of gemcitabine and cisplatin or gemcitabine and carboplatin plus dovitinib.

Methods

Patients with advanced solid tumors were enrolled in two parallel dose escalation arms (cisplatin- or carboplatin-based regimens). Treatment was administered with gemcitabine (1,000 mg/m2 on days 1 and 8), cisplatin (70 mg/m2), or carboplatin (AUC 5) on day 1, and dovitinib (orally on days 1–5, 8–12, and 15–19), every 21 days. The starting dose of dovitinib was 300 mg and was dose escalated in successive cohorts using 3 + 3 dose escalation rules.

Results

Fourteen patients with advanced solid tumors were enrolled, five to the cisplatin arm and nine to the carboplatin arm. Patients enrolled in the cisplatin arm received a median of two cycles of treatment (range 1–5), and patients enrolled in the carboplatin arm received a median of one cycle of treatment (range 1–4). There were no protocol-defined dose-limiting toxicities in the cisplatin arm. However, the cohort was closed due to the need for frequent dose delays and/or reductions and two patients experiencing severe thromboembolic events. There were two dose-limiting toxicities in the carboplatin arm at the starting dose level of dovitinib (both prolonged neutropenia), and the dose of dovitinib was de-escalated to 200 mg. Two additional dose-limiting toxicities (prolonged neutropenia and febrile neutropenia) occurred in the lower dose cohort, and the study was closed. No patients achieved an objective response to treatment.

Conclusions

Dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin was poorly tolerated due to myelosuppression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Folkman J (2006) Angiogenesis. Annu Rev Med 57:1–18. doi:10.1146/annurev.med.57.121304.131306

    Article  CAS  PubMed  Google Scholar 

  2. Chung AS, Lee J, Ferrara N (2010) Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 10:505–514. doi:10.1038/nrc2868

    Article  CAS  PubMed  Google Scholar 

  3. Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438:967–974. doi:10.1038/nature04483

    Article  CAS  PubMed  Google Scholar 

  4. Ferrara N (2002) VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2:795–803. doi:10.1038/nrc909

    Article  CAS  PubMed  Google Scholar 

  5. Turner N, Grose R (2010) Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10(2):116–129

    Article  CAS  PubMed  Google Scholar 

  6. Kerbel RS (2005) Therapeutic implications of intrinsic or induced angiogenic growth factor redundancy in tumors revealed. Cancer Cell 8(4):269–271

    Article  CAS  PubMed  Google Scholar 

  7. Brooks N, Kilgour E, Smith PD (2012) Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res 18:1855–1862. doi:10.1158/1078-0432.CCR-11-0699

    Article  CAS  PubMed  Google Scholar 

  8. Greenman C, Stephens P, Smith R et al (2007) Patterns of somatic mutation in human cancer genomes. Nature 446(7132):153–158

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Knowles MA (2008) Novel therapeutic targets in bladder cancer: mutation and expression of FGF receptors. Futur Oncol 4(1):71–83

    Article  CAS  Google Scholar 

  10. Iyer G, Al-Ahmadie H, Schultz N et al (2013) Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol 31(25):3133–3140. doi:10.1200/JCO.2012.46.5740

    Article  CAS  PubMed  Google Scholar 

  11. Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC (2010) FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One 5(11):e13821. doi:10.1371/journal.pone.0013821

    Article  PubMed Central  PubMed  Google Scholar 

  12. Quintela-Fandino M, Colomer R (2013) Dovitinib lactate: multikinase inhibitor antiangiogenic agent oncolytic. Drugs Future 38:81–89

    Article  Google Scholar 

  13. Angevin E, Lopez-Martin JA, Lin C-C et al (2013) Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Clin Cancer Res 19:1257–1268. doi:10.1158/1078-0432.CCR-12-2885

    Article  CAS  PubMed  Google Scholar 

  14. Andre F, Bachelot TD, Campone M et al (2011) A multicenter, open-label phase II trial of dovitinib, an FGFR1 inhibitor, in FGFR1 amplified and non-amplified metastatic breast cancer. J Clin Oncol 29:8–10

    Google Scholar 

  15. Azab AK, Azab F, Quang P et al (2011) FGFR3 is overexpressed Waldenstrom macroglobulinemia and its inhibition by dovitinib induces apoptosis and overcomes stroma-induced proliferation. Clin Cancer Res 17:4389–4399. doi:10.1158/1078-0432.CCR-10-2772

    Article  CAS  PubMed  Google Scholar 

  16. Sivanand S, Pena-Llopis S, Zhao H et al (2012) A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Sci Transl Med 4:137ra75–137ra75. doi:10.1126/scitranslmed.3003643

  17. Motzer RJ, Porta C, Bjarnason GA et al (2012) Phase III trial of dovitinib (TKI258) versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angiogenic (VEGF-targeted and mTOR inhibitor) therapies. ASCO Meet Abst 30:TPS4683. doi:10.1111/j.1464-410X.2012.11171.x

    Google Scholar 

  18. Tai W-T, Cheng A-L, Shiau C-W et al (2012) Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3. Mol Cancer Ther 11:452–463. doi:10.1158/1535-7163.MCT-11-0412

    Article  CAS  PubMed  Google Scholar 

  19. Sarker D, Molife R, Evans TR et al (2008) A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin Cancer Res 14(7):2075–2081. doi:10.1158/1078-0432.CCR-07-1466

    Article  CAS  PubMed  Google Scholar 

  20. Kim KB, Chesney J, Robinson D, Gardner H, Shi MM, Kirkwood JM (2011) Phase I/II and pharmacodynamic study of dovitinib (TKI258)—an inhibitor of fibroblast growth factor receptors and VEGF receptors-in patients with advanced melanoma. Clin Cancer Res. doi:10.1158/1078-0432.ccr-11-1747

    Google Scholar 

  21. Motzer RJ, Porta C, Vogelzang NJ et al (2014) Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol. doi:10.1016/S1470-2045(14)70030-0

    PubMed  Google Scholar 

  22. Galsky MD, Hahn NM, Powles T et al (2012) Gemcitabine, cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. Clin Genitourin Cancer 11(2):175–181. doi:10.1016/j.clgc.2012.10.001

    Article  PubMed  Google Scholar 

  23. Funakoshi T, Latif A, Galsky MD (2014) Safety and efficacy of addition of VEGFR or EGFR-family small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trials. Cancer Treat Rev 40(5):636–647

  24. Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J (2010) Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 28(13):2280–2285. doi:10.1200/JCO.2009.27.2757

    Article  CAS  PubMed  Google Scholar 

  25. Sonpavde G, Je Y, Schutz F et al (2013) Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol 87(1):80–89. doi:10.1016/j.critrevonc.2012.12.006

    Article  PubMed  Google Scholar 

  26. Seng S, Liu Z, Chiu SK et al (2012) Risk of venous thromboembolism in patients with cancer treated with cisplatin: a systematic review and meta-analysis. J Clin Oncol 30(35):4416–4426. doi:10.1200/JCO.2012.42.4358

    Article  CAS  PubMed  Google Scholar 

  27. Proverbs-Singh T, Chiu SK, Liu Z et al (2012) Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis. J Natl Cancer Inst 104(23):1837–1840. doi:10.1093/jnci/djs435

    Article  CAS  PubMed  Google Scholar 

  28. Cancer Genome Atlas Research Network (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. doi:10.1038/nature12965

    Google Scholar 

  29. Milowsky MI, Dittrich C, Duran Martinez I et al (2013) Final results of a multicenter, open-label phase II trial of dovitinib (TKI258) in patients with advanced urothelial carcinoma with either mutated or nonmutated FGFR3. ASCO Meet Abstr 31(6 Suppl.):255

    Google Scholar 

  30. Herrera-Abreu MT, Pearson A, Campbell J et al (2013) Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer. Cancer Discov 3(9):1058–1071. doi:10.1158/2159-8290.CD-12-0569

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  31. Sequist LV, Cassier P, Varga A et al (2014) Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors. In: American Association for Cancer Research 2014 annual meeting, p CT326

Download references

Acknowledgments

This research was supported by Novartis and by Grant UL1TR000067 from the National Center for Research Resources, National Institutes of Health.

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 1 Gustave L Levy Place, New York, NY, 10029, USA

    Matthew D. Galsky, Marshall Posner, Randall F. Holcombe, Krzysztof Misiukiewicz, Che-Kai Tsao, Rothschild Soto, Kiev Gimpel-Tetra, Nancy Lowe & William K. Oh

  2. Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Karen M. Lee

  3. Department of Health Evidence and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    James Godbold

Authors
  1. Matthew D. Galsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marshall Posner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Randall F. Holcombe
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Karen M. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Krzysztof Misiukiewicz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Che-Kai Tsao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. James Godbold
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Rothschild Soto
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kiev Gimpel-Tetra
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Nancy Lowe
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. William K. Oh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthew D. Galsky.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Galsky, M.D., Posner, M., Holcombe, R.F. et al. Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors. Cancer Chemother Pharmacol 74, 465–471 (2014). https://doi.org/10.1007/s00280-014-2518-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-014-2518-5

Keywords

Search

Navigation